@article{d625144c12bb484b9e6bf0d74d783e35,
title = "Recurrent Melioidosis in the Darwin Prospective Melioidosis Study: Improving Therapies Mean that Relapse Cases Are Now Rare",
abstract = "The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years. ",
keywords = "ceftazidime, meropenem, antibiotic therapy, article, bacterial strain, Burkholderia pseudomallei, clinical article, clinical feature, disease duration, disease severity, drug effect, human, melioidosis, priority journal, rare disease, recurrent infection, reinfection, relapse, survival rate, treatment planning, Humans, Incidence, Melioidosis, Prospective Studies, Recurrence",
author = "Derek Sarovich and Linda Ward and Erin Price and Mark Mayo and Matthew Pitman and Robert Baird and Bart Currie",
year = "2014",
month = feb,
doi = "10.1128/JCM.02239-13",
language = "English",
volume = "52",
pages = "650--653",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",
}